Spironolactone After Liver Transplant

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Atrium Health; Carolinas Healthcare System
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• liver transplant

Exclusion Criteria:

• dual organ transplant